Impact Factor 2021: 3.041 (@Clarivate Analytics)
5-Year Impact Factor: 2.776 (@Clarivate Analytics)
Impact Factor Rank: 10/24, Q2 (Tropical Medicine)
  • Users Online: 684
  • Print this page
  • Email this page
Year : 2019  |  Volume : 12  |  Issue : 12  |  Page : 531-536

Multi-targeting cytotoxic drug leads from mushrooms

1 Phytomedicine & Phytochemistry Division, Raghavendra Institute of Pharmaceutical Education & Research (RIPER) (AUTONOMOUS) campus, Anantapuramu, AP, India
2 Department of Pharmacology, Karpagam College of Pharmacy, Othakkalmadapam, Coimbatore 32, Tamilnadu, India
3 RERDS-CPR, Raghavendra Institute of Pharmaceutical Education & Research (RIPER) (AUTONOMOUS), Anantapuramu, AP, India
4 Pharmacognosy and Phytotherapy Research Laboratory, Division of Pharmacognosy, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
5 School of Crop Production Technology, Suranaree University of Technology, Thailand

Correspondence Address:
MVNL Chaitanya
Phytomedicine & Phytochemistry Division, Raghavendra Institute of Pharmaceutical Education & Research Saigram, Near SK University, Krishnamreddypalli Cross, Chiyyedu, Anantapuramu-515721. A.P
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1995-7645.272482

Rights and Permissions

Due to genetic and epigenetic mechanisms, cancer have become a resistant disease and there is a need for new molecules having multiple targeting action that promotes apoptosis. Phyto-molecules having multiple targeting anticancer activity are in high demand and there is less documentation or information available on these metabolites. It is evident that mushrooms are became the store houses of new anticancer molecules and mushrooms like Agaricus blazei, Antrodia camphorate, Albatrellus confluens, Bolteus badius, Cordyceps militaris, Clitocybe maxima, Funalia trogii, Grifola frondosa, and Inocybe umbrinella, are some of the medicinal mushrooms reported for their cytotoxic activity. Cytotoxic molecules like lentinan, grifolin, illudin-S, psilocybin, ganoderic acid, theanine, and hispolon, have been isolated from various mushroom species. However, studies have been limited only to in vitro cytotoxic mechanisms and very few trials have been conducted to prove the clinical efficacy of these drug leads. Hence, the current review focuses on new anticancer metabolites isolated from various mushrooms having multiple targeting mechanisms in cancer. However, an extensive research is needed to define the biosynthesis and clinical mechanism of these multiple acting metabolites. This review provides a platform for researchers new anticancer drugs and to bring out potent multiple acting anticancer newer drugs.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded515    
    Comments [Add]    
    Cited by others 2    

Recommend this journal